Doctors Revision

Emergency Medicine & Critical Care

Hypoglycaemia Management

A clinical condition characterized by abnormally low blood glucose levels (typically <3.0 mmol/L or <55 mg/dl), leading to neuroglycopenic and autonomic symptoms. Requires prompt recognition and treatment to prevent neurological damage.

Also known as: Low Blood Sugar

Open in the interactive guide
On this page

Referral and warning signs

When to refer

Refer to HC4/Hospital if: Patient remains unconscious or confused despite glucose administration. Hypoglycaemia is severe or recurrent without obvious cause. Caused by long-acting insulin or oral hypoglycaemic agents (requires prolonged observation/admission). Suspected underlying cause requires hospital investigation (e.g., insulinoma, adrenal insufficiency).

Red flags

  • Unconsciousness or coma
  • Active seizures
  • Persistent confusion or neurological deficit despite glucose correction
  • Hypoglycaemia caused by long-acting insulin or sulphonylurea agent
  • Recurrent episodes without clear explanation
  • Inability to maintain safe glucose levels orally

Signs and symptoms

  • Autonomic symptoms (early): Sweating (diaphoresis), Tremors, Palpitations, Anxiety, Nervousness, Hunger
  • Neuroglycopenic symptoms (later/severe): Dizziness, Confusion, Difficulty concentrating, Weakness, Drowsiness, Behavioural changes, Blurred vision, Slurred speech, Headache, Seizures, Loss of consciousness (coma)

Risk factors

  • Diabetes mellitus treatment (Insulin overdose, excessive dose of sulphonylureas, missed meals, excessive exercise)
  • Severe Sepsis or critical illness
  • Malaria (especially severe malaria, or due to quinine treatment)
  • Severe malnutrition / Starvation
  • Hepatic disease (liver failure)
  • Renal failure
  • Excessive alcohol intake (especially without food)
  • Adrenal insufficiency (cortisol deficiency)
  • Growth hormone deficiency
  • Insulinoma (rare pancreatic tumour)
  • Prematurity (infants)
  • Post-gastrectomy (dumping syndrome)

Diagnosis

Clinical assessment

Suspicion based on presence of symptoms (autonomic or neuroglycopenic) in a patient with risk factors. Confirmation requires blood glucose measurement.

Investigations

  • Point-of-care blood glucose measurement (fingerstick test). Confirmed if <3.0 mmol/L (55 mg/dl) with symptoms.
  • Laboratory plasma glucose (more accurate).
  • Further investigations to determine underlying cause if not obvious (e.g., investigations for sepsis, malaria test, liver function tests, cortisol level, insulin/C-peptide levels - usually hospital level).

Diagnostic criteria

Whipple's Triad is classically used: 1. Symptoms consistent with hypoglycaemia. 2. Low plasma glucose concentration measured at the time of symptoms. 3. Relief of symptoms after the glucose level is raised.

Management

Non-pharmacological management

  • If patient is conscious, alert, and able to swallow safely:
  • Give fast-acting oral carbohydrate: 15-20g of glucose (e.g., 3-4 glucose tablets, 1/2 cup fruit juice or sugary non-diet soda, 3 teaspoons or packets of sugar dissolved in water).
  • Recheck blood glucose after 15 minutes.
  • If still low, repeat oral glucose.
  • Once glucose is >4.0 mmol/L, provide a snack containing complex carbohydrates and protein (e.g., bread, crackers with cheese, milk) to prevent recurrence, especially if next meal is >1 hour away or if caused by long-acting insulin/oral agent.

Pharmacological treatment

  • If patient is unconscious, having seizures, or unable to swallow safely:
  • Secure airway, breathing, circulation (ABC).
  • Establish IV access.
  • Adults: Give Glucose 50% 20-50 ml IV slowly (over 1-3 minutes). Flush line afterwards. Follow with Dextrose 10% IV infusion if needed until patient is fully conscious and able to eat.
  • Children: Give Dextrose 10% IV 2-5 ml/kg bolus slowly. Follow with Dextrose 10% infusion if needed.
  • If IV access cannot be obtained quickly: Glucagon 1 mg IM/SC (Adults/Children >25kg); 0.5mg (Children <25kg). Note: Glucagon may be ineffective in starvation, alcohol-induced hypoglycaemia, or adrenal insufficiency.
  • Treat underlying cause (e.g., adjust diabetes medication, treat sepsis/malaria).
  • Follow specific Ugandan treatment algorithms/guidelines.

Monitoring

Monitor blood glucose frequently (e.g., every 15-30 minutes initially, then hourly) until stable and patient is conscious and eating. Continue monitoring for several hours, especially if caused by long-acting insulin or oral hypoglycaemic agents (e.g., sulphonylureas - risk of recurrence is high, may require admission and prolonged infusion). Monitor neurological status.

Complications

  • Seizures
  • Permanent neurological damage (brain damage) if severe or prolonged
  • Coma
  • Cardiac arrhythmias
  • Injury from falls or accidents during episode
  • Death

Prevention

  • Patient education (especially for diabetics) on recognizing early symptoms and self-treatment.
  • Regular meals and snacks for those at risk (diabetics, post-gastrectomy).
  • Appropriate dosing and timing of insulin and oral hypoglycaemic agents.
  • Regular blood glucose monitoring for diabetics.
  • Advise patients at risk to carry fast-acting glucose (tablets, gel, sugar packets) at all times.
  • Advise diabetic patients to wear medical identification (bracelet/tag).

Patient education

  • Teach patients (especially diabetics) and their families about symptoms of hypoglycaemia.
  • Explain how to treat mild-moderate episodes with oral glucose.
  • Explain when to seek emergency help.
  • Discuss prevention strategies (meal timing, medication adherence, glucose monitoring).
  • Importance of carrying fast-acting glucose and medical ID.
  • How to use glucagon kit if prescribed.

Uganda-specific notes

Note preparation instructions for Dextrose 10% (from D5% and D50%). Always consider severe malaria and sepsis as potential causes of hypoglycaemia, especially in febrile patients with altered mental status. Quinine therapy for malaria can also induce hypoglycaemia.

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 1, Section 1.1.6

Scroll to Top